Literature DB >> 18032608

Chronic stimulation of Nod2 mediates tolerance to bacterial products.

Matija Hedl1, Jing Li, Judy H Cho, Clara Abraham.   

Abstract

The Toll-like receptor (TLR) and nucleotide-binding oligomerization domain (Nod) families of proteins are critical for bacterial recognition, and, acutely, this frequently leads to proinflammatory responses. Polymorphisms in Nod2 (CARD 15) are associated with an increased likelihood of developing Crohn's disease. However, it is not yet clear how Nod2 dysfunctions lead to defects in human intestinal immune homeostasis. Studies to date have focused on functions after acute, rather than chronic, Nod2 stimulation. However, the intestine is an environment of chronic bacterial product exposure with tolerance to luminal flora. We therefore hypothesized that long-term Nod2 stimulation contributes to down-regulation of inflammatory responses from innate immune receptors. We found that pretreatment with muramyl dipeptide (MDP), a ligand for Nod2, significantly decreased production of the proinflammatory cytokines TNF-alpha, IL-8, and IL-1beta upon Nod2, TLR4, and TLR2 restimulation in primary human monocyte-derived macrophages from a large cohort of individuals. Importantly, TNF-alpha-induced production of proinflammatory cytokines remained intact in these same cells. MDP-stimulated macrophages from Crohn's disease-relevant Leu1007insC Nod2 homozygote individuals were deficient in their ability to cross-tolerize to subsequent treatment with TLR2 and TLR4 ligands. We show that acute Nod2 stimulation induced IRAK-1 activation, and that chronic MDP treatment down-regulated IRAK-1 activation upon Nod2 or TLR4 restimulation. In a subset of individuals, chronic Nod2 stimulation induced expression of the IRAK-1 inhibitory protein IRAK-M. Significantly, intestinal macrophages exhibit tolerance to MDP per production of inflammatory cytokines. These results illustrate a role for chronic stimulation of Nod2 in mediating tolerance to bacterial products.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032608      PMCID: PMC2148308          DOI: 10.1073/pnas.0706097104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages.

Authors:  Kuniko Nakayama; Shu Okugawa; Shintaro Yanagimoto; Takatoshi Kitazawa; Kunihisa Tsukada; Miki Kawada; Satoshi Kimura; Koichi Hirai; Yohtaroh Takagaki; Yasuo Ota
Journal:  J Biol Chem       Date:  2003-12-04       Impact factor: 5.157

Review 2.  Inferences, questions and possibilities in Toll-like receptor signalling.

Authors:  Bruce Beutler
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

3.  RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs.

Authors:  Jong-Hwan Park; Yun-Gi Kim; Christine McDonald; Thirumala-Devi Kanneganti; Mizuho Hasegawa; Mathilde Body-Malapel; Naohiro Inohara; Gabriel Núñez
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

4.  hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells.

Authors:  Stephan R Vavricka; Mark W Musch; Jonathan E Chang; Yasushi Nakagawa; Kittiporn Phanvijhitsiri; Tonya S Waypa; Didier Merlin; Olaf Schneewind; Eugene B Chang
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

5.  Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

Authors:  Michael Economou; Thomas A Trikalinos; Konstantinos T Loizou; Epameinondas V Tsianos; John P A Ioannidis
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

6.  Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses.

Authors:  Jason S Damiano; Vasco Oliveira; Kate Welsh; John C Reed
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

7.  Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations.

Authors:  Jing Li; Thomas Moran; Eric Swanson; Christina Julian; Jeremy Harris; Denise K Bonen; Matija Hedl; Dan L Nicolae; Clara Abraham; Judy H Cho
Journal:  Hum Mol Genet       Date:  2004-06-15       Impact factor: 6.150

8.  Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis.

Authors:  Y Ogura; S Lala; W Xin; E Smith; T A Dowds; F F Chen; E Zimmermann; M Tretiakova; J H Cho; J Hart; J K Greenson; S Keshav; G Nuñez
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

9.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

10.  Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae.

Authors:  Bastian Opitz; Anja Püschel; Bernd Schmeck; Andreas C Hocke; Simone Rosseau; Sven Hammerschmidt; Ralf R Schumann; Norbert Suttorp; Stefan Hippenstiel
Journal:  J Biol Chem       Date:  2004-06-23       Impact factor: 5.157

View more
  119 in total

1.  Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling.

Authors:  Md A Nahid; Minoru Satoh; Edward K L Chan
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

Review 2.  Gut microbiota and related diseases: clinical features.

Authors:  Vincenzo Stanghellini; Giovanni Barbara; Cesare Cremon; Rosanna Cogliandro; Alexandra Antonucci; Veronica Gabusi; Chiara Frisoni; Roberto De Giorgio; Valentina Grasso; Mauro Serra; Roberto Corinaldesi
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

3.  RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.

Authors:  Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Atsushi Kitani; Masaki Tajima; Ivan J Fuss; Masatoshi Kudo; Warren Strober
Journal:  Int Immunol       Date:  2019-09-18       Impact factor: 4.823

4.  Activation of human macrophages by bacterial components relieves the restriction on replication of an interferon-inducing parainfluenza virus 5 (PIV5) P/V mutant.

Authors:  Caitlin M Briggs; Robert C Holder; Sean D Reid; Griffith D Parks
Journal:  Microbes Infect       Date:  2010-12-24       Impact factor: 2.700

5.  NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis.

Authors:  Simon A Hirota; Jeffrey Ng; Alan Lueng; Maitham Khajah; Ken Parhar; Yan Li; Victor Lam; Mireille S Potentier; Kelvin Ng; Misha Bawa; Donna-Marie McCafferty; Kevin P Rioux; Subrata Ghosh; Ramnik J Xavier; Sean P Colgan; Jurg Tschopp; Daniel Muruve; Justin A MacDonald; Paul L Beck
Journal:  Inflamm Bowel Dis       Date:  2010-09-24       Impact factor: 5.325

6.  Neutrophils activate alveolar macrophages by producing caspase-6-mediated cleavage of IL-1 receptor-associated kinase-M.

Authors:  Hiroshi Kobayashi; Anna Nolan; Bushra Naveed; Yoshihiko Hoshino; Leopoldo N Segal; Yoko Fujita; William N Rom; Michael D Weiden
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

Review 7.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

8.  JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages.

Authors:  Matija Hedl; Deborah D Proctor; Clara Abraham
Journal:  J Immunol       Date:  2016-09-23       Impact factor: 5.422

9.  An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes.

Authors:  Jie Yan; Matija Hedl; Clara Abraham
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

Review 10.  New insights into the epigenetics of inflammatory rheumatic diseases.

Authors:  Esteban Ballestar; Tianlu Li
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.